Lantheus Holdings, Inc. NASDAQ:LNTH

Lantheus Holdings stock price today

$55.32
-36.74
-39.92%
Financial Health
0
1
2
3
4
5
6
7
8
9

Lantheus Holdings stock price monthly change

-25.40%
month

Lantheus Holdings stock price quarterly change

-25.40%
quarter

Lantheus Holdings stock price yearly change

+49.68%
year

Lantheus Holdings key metrics

Market Cap
6.21B
Enterprise value
6.08B
P/E
210.61
EV/Sales
6.50
EV/EBITDA
74.33
Price/Sales
6.32
Price/Book
13.22
PEG ratio
1.51
EPS
6.72
Revenue
1.36B
EBITDA
559.92M
Income
460.53M
Revenue Q/Q
23.00%
Revenue Y/Y
32.97%
Profit margin
3%
Oper. margin
3.87%
Gross margin
62.21%
EBIT margin
3.87%
EBITDA margin
41%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Lantheus Holdings stock price history

Lantheus Holdings stock forecast

Lantheus Holdings financial statements

Average Price Target
Last Year

$159

Potential upside: 187.41%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Lantheus Holdings, Inc. (NASDAQ:LNTH): Profit margin
Jun 2023 321.7M 94.13M 29.26%
Sep 2023 319.94M 131.95M 41.24%
Dec 2023 353.99M 103.38M 29.2%
Mar 2024 369.97M 131.06M 35.43%
Lantheus Holdings, Inc. (NASDAQ:LNTH): Debt to assets
Jun 2023 1337720000 785.07M 58.69%
Sep 2023 1521610000 822.85M 54.08%
Dec 2023 1651149000 835.25M 50.59%
Mar 2024 1831334000 885.79M 48.37%
Lantheus Holdings, Inc. (NASDAQ:LNTH): Cash Flow
Jun 2023 -32.26M -20.69M -4.05M
Sep 2023 116.73M 83.21M 108K
Dec 2023 112.28M -12.06M -450K
Mar 2024 127.23M -106.52M -16.84M

Lantheus Holdings alternative data

Lantheus Holdings, Inc. (NASDAQ:LNTH): Employee count
Sep 2023 698
Oct 2023 698
Nov 2023 698
Dec 2023 698
Jan 2024 698
Feb 2024 698
Apr 2024 834
May 2024 834
Jun 2024 834
Jul 2024 834

Lantheus Holdings other data

98.26% +2.19%
of LNTH is owned by hedge funds
66.31M +1.34M
shares is hold by hedge funds

Lantheus Holdings, Inc. (NASDAQ:LNTH): Insider trades (number of shares)
Period Buy Sel
Dec 2023 0 10341
Jan 2024 0 341
Feb 2024 0 341
Mar 2024 0 158706
Apr 2024 0 341
May 2024 0 35266
Jun 2024 0 341
Jul 2024 0 14667
Aug 2024 0 31481
Nov 2024 0 23487
Transaction Date Insider Security Shares Price per share Total value Source
Option
MARKISON BRIAN A director, officer.. Common Stock 16,666 $6 $99,996
Option
MARKISON BRIAN A director, officer.. Common Stock 16,102 $12.42 $199,987
Option
MARKISON BRIAN A director, officer.. Stock Option (right to buy) 32,768 $9.21 $301,793
Sale
MARSHALL ROBERT J. JR. officer: CFO and .. Common Stock 10,000 $81.2 $812,000
Sale
BLANCHFIELD PAUL officer: President
Common Stock 2,000 $79.65 $159,300
Sale
HEINO MARY ANNE director Common Stock 7,487 $86.32 $646,278
Sale
HEINO MARY ANNE director Common Stock 400 $86.93 $34,772
Sale
HEINO MARY ANNE director Common Stock 2,900 $88.78 $257,462
Sale
HEINO MARY ANNE director Common Stock 700 $89.58 $62,706
Sale
THRALL JAMES H director
Common Stock 1,000 $98.52 $98,520
Thursday, 12 December 2024
seekingalpha.com
Wednesday, 20 November 2024
fool.com
globenewswire.com
Wednesday, 13 November 2024
globenewswire.com
Monday, 11 November 2024
globenewswire.com
Friday, 8 November 2024
seekingalpha.com
Wednesday, 6 November 2024
seekingalpha.com
Monday, 4 November 2024
globenewswire.com
Wednesday, 23 October 2024
globenewswire.com
Sunday, 15 September 2024
globenewswire.com
Thursday, 5 September 2024
globenewswire.com
Wednesday, 28 August 2024
globenewswire.com
Monday, 12 August 2024
seekingalpha.com
marketwatch.com
Wednesday, 31 July 2024
globenewswire.com
Wednesday, 17 July 2024
globenewswire.com
Monday, 15 July 2024
globenewswire.com
Wednesday, 10 July 2024
globenewswire.com
fool.com
investors.com
Monday, 8 July 2024
globenewswire.com
Thursday, 27 June 2024
globenewswire.com
Monday, 24 June 2024
zacks.com
Friday, 21 June 2024
zacks.com
zacks.com
Thursday, 20 June 2024
globenewswire.com
Wednesday, 19 June 2024
zacks.com
Tuesday, 18 June 2024
zacks.com
Wednesday, 12 June 2024
zacks.com
zacks.com
  • What's the price of Lantheus Holdings stock today?

    One share of Lantheus Holdings stock can currently be purchased for approximately $55.32.

  • When is Lantheus Holdings's next earnings date?

    Unfortunately, Lantheus Holdings's (LNTH) next earnings date is currently unknown.

  • Does Lantheus Holdings pay dividends?

    No, Lantheus Holdings does not pay dividends.

  • How much money does Lantheus Holdings make?

    Lantheus Holdings has a market capitalization of 6.21B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 38.65% to 1.3B US dollars.

  • What is Lantheus Holdings's stock symbol?

    Lantheus Holdings, Inc. is traded on the NASDAQ under the ticker symbol "LNTH".

  • What is Lantheus Holdings's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Lantheus Holdings?

    Shares of Lantheus Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Lantheus Holdings's key executives?

    Lantheus Holdings's management team includes the following people:

    • Ms. Mary Anne Heino Chief Executive Officer, Pres & Director(age: 65, pay: $1,430,000)
    • Mr. Robert J. Marshall Jr., CFA Chief Financial Officer & Treasurer(age: 58, pay: $648,620)
  • How many employees does Lantheus Holdings have?

    As Jul 2024, Lantheus Holdings employs 834 workers.

  • When Lantheus Holdings went public?

    Lantheus Holdings, Inc. is publicly traded company for more then 10 years since IPO on 25 Jun 2015.

  • What is Lantheus Holdings's official website?

    The official website for Lantheus Holdings is lantheus.com.

  • Where are Lantheus Holdings's headquarters?

    Lantheus Holdings is headquartered at 331 Treble Cove Road, North Billerica, MA.

  • How can i contact Lantheus Holdings?

    Lantheus Holdings's mailing address is 331 Treble Cove Road, North Billerica, MA and company can be reached via phone at 978 671 8001.

  • What is Lantheus Holdings stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Lantheus Holdings in the last 12 months, the avarage price target is $159. The average price target represents a 187.41% change from the last price of $55.32.

Lantheus Holdings company profile:

Lantheus Holdings, Inc.

lantheus.com
Exchange:

NASDAQ

Full time employees:

834

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

331 Treble Cove Road
North Billerica, MA 01862

CIK: 0001521036
ISIN: US5165441032
CUSIP: 516544103